Neurology and Neurosurgery

1-16 of 50

• 

  MinuteCE®

  Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)

  1.00 credit 10 episodes

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 credit 10 episodes

• 

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  MinuteCE®

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  1.00 program credit

• 

  RestartResume

  Target Locked in gMG: Why T2T Matters

  RestartResume

  Target Locked in gMG: Why T2T Matters

  MinuteCE®

  Target Locked in gMG: Why T2T Matters

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Minimal By Design: Define MSE Endpoints

  RestartResume

  Minimal By Design: Define MSE Endpoints

  MinuteCE®

  Minimal By Design: Define MSE Endpoints

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Turning Flares Into Function: Flag Uncontrolled Disease

  RestartResume

  Turning Flares Into Function: Flag Uncontrolled Disease

  MinuteCE®

  Turning Flares Into Function: Flag Uncontrolled Disease

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  When to Begin FcRn: Initiation Criteria, Key Evidence

  RestartResume

  When to Begin FcRn: Initiation Criteria, Key Evidence

  MinuteCE®

  When to Begin FcRn: Initiation Criteria, Key Evidence

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  MinuteCE®

  The IgG Clock: Redose Using IgG Kinetics

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Escalate With Intention: Stepwise, Target-Anchored Moves

  RestartResume

  Escalate With Intention: Stepwise, Target-Anchored Moves

  MinuteCE®

  Escalate With Intention: Stepwise, Target-Anchored Moves

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Shared Goals, Shared Gains: Align With Patient Preferences

  RestartResume

  Shared Goals, Shared Gains: Align With Patient Preferences

  MinuteCE®

  Shared Goals, Shared Gains: Align With Patient Preferences

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  The 2-Point Signal: Apply ≥2-Point Rule

  RestartResume

  The 2-Point Signal: Apply ≥2-Point Rule

  MinuteCE®

  The 2-Point Signal: Apply ≥2-Point Rule

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  RestartResume

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  MinuteCE®

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  RestartResume

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  CME/CE

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  0.50 credits

  • 

    

    Neelam Goyal, MD

  • 

    

    Christyn Edmundson, MD

  0.50 credits

• 

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics

  CME/CE

  Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics

  0.75 credits

  • 

    

    Vera Bril, MD

  • 

    

    Neelam Goyal, MD

  0.75 credits

• 

  MinuteCE®

  Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology

  1.00 credit 10 episodes

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  • 

    

    Hans Katzberg, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  CME/CE

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  0.75 credits

  • 

    

    Vera Bril, MD

  • 

    

    Jonathan Strober, MD

  0.75 credits

• 

  RestartResume

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  RestartResume

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  MinuteCE®

  Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• Prev
• 1
• 2
• 3
• 4
• Next